NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Korea Innovative Medicines Consortium

Korea Innovative Medicines Consortium

Seoulkimco.or.kr

Overview

Korea Innovative Medicines Consortium is a non-profit foundation established by South Korean pharmaceutical and biotechnology companies to serve as a collaboration platform for co-investment and co-development in the bio-pharma industry.

Year Founded

2020

Portfolio Companies

3

Investments

Korea Innovative Medicines Consortium investments
CompanyDateStageLead
NeumousJul 2025Series ACo-investor
GeditJan 2024Series A ExtensionCo-investor
BreezeBioJan 2024Series A ExtensionCo-investor

Sector & Stage Mix

Industry, funding stage, and valuation band breakdowns.

Premium
SeedSeries ASeries BGrowth

Unlock portfolio analytics

Sign up to view full sector, stage, and valuation breakdowns for this investor.

Investment Activity

Yearly cadence, pace, and funding raised over time.

Premium
2021
2022
2023
2024
2025
2026

Unlock portfolio analytics

Sign up to explore yearly investment trends and funding raised over time.

FAQ

Firmographic Details

HeadquartersSeoul
Year Founded2020

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.